anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Both humoral and cell-mediated immunity of the patient affected by multiple myeloma (MM) are impaired; thus, infection is the main cause of the onset of symptoms and death caused by MM. Bortezomib is a first-line drug approved for patients with multiple myeloma (MM) and has significantly increased their overall survival. However, bortezomib-induced peripheral neuropathy (PN) remains a significant side effect that has led to its discontinuation in some patients. Guillain-Barre syndrome (GBS) is thought to be related to immune damage, and most patients have cytomegalovirus (CMV), Epstein-Barr virus (EBV), or mycoplasma infection before onset. Cases of GBS secondary to MM are rare.
METHODS: We provide a case of GBS caused by cytomegalovirus infection after MM treatment, and briefly review the existing literature.
RESULTS: Secondary GBS after MM. This patient received active treatment. The clinical symptoms are gradually improving.
CONCLUSIONS: The use of bortezomib has the risk of reactivating the virus. It is more about the reactivation of hep-atitis B virus. Nonetheless, cytomegalovirus and Epstein-Barr virus shall have our attention. Patients with MM need to monitor CMV, regularly, especially during the treatment of bortezomib. At the same time, they also need to closely monitor the symptoms and signs of the nervous system to guard against the occurrence of GBS.
Oral Tenofovir disoproxil fumarate/Emtricitabine and Lopinavir/Ritonavir for 12 weeks followed by treatment interruption if CD4 count is 450 mm\^3 or higher. When CD4 count is less than 350 mm\^3 on two separate, consecutive measurements during treatment interruption, therapy will be resumed.
ETHNOPHARMACOLOGICAL RELEVANCE: Tetrastigma hemsleyanum Diels et Gilg, is one of the perennial evergreen plants with grass vine, which has obvious curative effect on severe infectious diseases. Although Tetrastigma hemleyanum has long been recognized for its capacity of antipyretic and antitoxic, its specific mechanism is unknown.
AIM OF THE STUDY: To evaluate the antipyretic effect of Tetrastigma hemleyanum polysaccharide (THP) on mice with dry yeast-induced fever, and to explore its specific antipyretic mechanism.
METHODS: In this study, THP was administered by aerosol in febrile mice. The rectal temperatures of treated animals were monitored at different time points. Histopathological evaluation and various inflammatory indexes were used to assess inflammatory damage. The concentration variations of the central neurotransmitter, endocrine system, substance and energy metabolism indicators were measured to explore the physiological mechanism. Quantitative real-time PCR, Western bolt and Immunohistochemistry were performed to identify the correlation between antipyretic and TLR4/NF-κB signaling pathway.
RESULTS: THP reduced the body temperature of febrile mice induced by dry yeast, as well as the levels of thermogenic cytokines and downregulated the contents of thermoregulatory mediators. THP alleviated the pathological damage of liver and hypothalamus caused by fever. In addition, THP decreased the secretion of thyroid hormone, substance and energy metabolism related indicators. Furthermore, THP significantly suppressed TLR4/NF-κB signaling pathway-related indicators.
CONCLUSIONS: In conclusion, our results suggest that inhaled THP exerts antipyretic effect by mediating the thermoregulatory mediator, decreasing the content of pyrogenic factors to lower the body temperature, and eventually restoring the high metabolic level in the body to normal via inhibiting TLR4/NF-κB signaling pathway. The study provides a reasonable pharmacodynamic basis for the treatment of polysaccharide in febrile-related diseases.
The treatment will be administrated as neoadjuvant 8 weeks before surgery. After surgical intervention the treatment will be administered up to 96 weeks. Treatment will be discontinued in case of unacceptable toxicity or disease progression.
Participants will complete a virtual reality (VR) exercise tutorial (Supernatural gameplay) and a Supernatural affect measurement workout (Flow or Boxing) in the Behavioural Medicine Lab (UVic). The tutorial will include watching Supernatural YouTube instructional videos, then completing a Supernatural training (\~5-6 min), a 'getting started' low intensity Supernatural workout (\~3 min), a low intensity Supernatural workout (\~3 min), and a medium intensity Supernatural workout (\~3 min). Participants will then complete the affect measurement medium intensity Supernatural workout (18-20 min). Participants will be provided a Virtual Reality headset (i.e., Meta Quest 3 headset) equipped with a Supernatural account for 10 weeks and will be instructed to participate in 75 minutes of medium intensity Supernatural physical activity per week which is equivalent to 75 minutes of vigorous physical activity (in line with the Canadian physical activity guidelines).
BACKGROUND: Bone morphogenetic protein 4 (BMP4) is a potent inhibitor of breast cancer metastasis. However, a tumor-promoting effect of BMP4 is reported in other tumor types, especially when SMAD4 is inactive.
METHODS: To assess the requirement for SMAD4 in BMP4-mediated suppression of metastasis, we knocked down SMAD4 in two different breast tumors and enforced SMAD4 expression in a third line with endogenous SMAD4 deletion. In addition, we assessed the requirement for SMAD4 in tumor cell-specific BMP signalling by expression of a constitutively active BMP receptor. Delineation of genes regulated by BMP4 in the presence or absence of SMAD4 was assessed by RNA sequencing and a BMP4-induced gene, MYO1F was assessed for its role in metastasis. Genes regulated by BMP4 and/or SMAD4 were assessed in a publicly available database of gene expression profiles of breast cancer patients.
RESULTS: In the absence of SMAD4, BMP4 promotes primary tumor growth that is accompanied by increased expression of genes associated with DNA replication, cell cycle, and MYC signalling pathways. Despite increased primary tumor growth, BMP4 suppresses metastasis in the absence of tumor cell expression of SMAD4. Consistent with the anti-metastatic activity of BMP4, enforced signalling through the constitutively active receptor in SMAD4 positive tumors that lacked BMP4 expression still suppressed metastasis, but in the absence of SMAD4, the suppression of metastasis was largely prevented. Thus BMP4 is required for suppression of metastasis regardless of tumor SMAD4 status. The BMP4 upregulated gene, MYO1F, was shown to be a potent suppressor of breast cancer metastasis. Gene signature upregulated by BMP4 in the absence of SMAD4 was associated with poor prognosis in breast cancer patients, whereas gene signature upregulated by BMP4 in the presence of SMAD4 was associated with improved prognosis.
CONCLUSIONS: BMP4 expression is required for suppression of metastasis regardless of the SMAD4 status of the tumor cells. Since BMP4 is a secreted protein, we conclude that it can act both in an autocrine manner in SMAD4-expressing tumor cells and in a paracrine manner on stromal cells to suppress metastasis. Deletion of SMAD4 from tumor cells does not prevent BMP4 from suppressing metastasis via a paracrine mechanism.
The study population consists of 50 healthy volunteers who have not received upper gastrointestinal surgery and 100 patients treated with surgery more than one year ago (50 open and 50 minimally invasive). Chest wall movement will be measured using a 3D optical motion system and the investigators will establish if inertial measurement units placed strategically on the chest wall are able to quantify chest expansion and lung capacity. Data will be acquired during different breathing patterns and during use of an incentive spirometry. Pulmonary function tests will be undertaken in all patients and the investigators will also collect clinical data concerning health-related quality of life and other concomitant medical conditions. The target outcome of this study is to determine whether the 3D motion capture and wearable systems are reliable in the measurement of chest wall movement after surgical removal of esophagus and the validity and patient acceptability of wearable system, as well as the ability of distinguishing open and minimally invasive surgical approach. A tailored physiotherapy may be developed following this study in order to improve chest wall movement and objectively measure this using the wearable system. This can then be implemented in a clinical trial to provide the evidence base to for patient-tailored physiotherapy following major cancer surgery and to optimise the respiratory function.
A composition for the diagnosis of diseases relating to amyloid which con tains either a compound represented by the general formula (I): [wherein X r epresents O, etc.; R1, R3, R4, R5, R6, R8, and R9 each represents hydrogen, etc.; R2 represents halogeno, etc.; and R7 represents dimethylamino, etc.] o r a compound obtained by labeling that compound with a radionuclide or conta ins a pharmaceutically acceptable salt of any of these compounds. The compou nd represented by the general formula (I) has high bonding specificity for a myloid ß-protein, is apt to highly pass through the blood-brain barrier, and has the property of rapidly disappearing from the areas excluding senile pl aques in the brain.
The present invention relates to a corneum softening and whitening cosmetic composition including alpha hydroxy acids (AHA), urea, and niacinamide. More specifically, the present invention relates to a skin external application composition for softening corneum and having maintained formulation stability by including AHA, AHA alkali metal salts, and urea as active ingredients. The corneum softening and whitening cosmetic composition further comprises niacinamide, so a whitening effect is also ensured. The composition according to the present invention and a cosmetic product produced through the same has excellent corneum softening and skin whitening effects. In particular, the composition and the cosmetic product are effective for corneum of an elbow or a heel, and formulation pH is maintained at 4.0-8.0 which are suitable as a cosmetic product. Thus, active ingredients can be stably maintained without being decomposed in the composition.
PURPOSE:A detergent for a tooth or artificial denture, having a powerful removing effect on tobacco tar with high safety, and comprising phytic acid or a derivative thereof as an active constituent. CONSTITUTION:A detergent for a tooth or artificial denture comprising 0.1- 50wt% phytic acid (myo-inositol hexaphosphate) or a derivative thereof calculated  as the phytic acid, in the form of a solution, paste, tablet, powder or granule. A  tooth or denture on which tobacco tar is deposited is coated, brought into contact or  brushed with the detergent to swell and remove the tar. Although powerful in showing the removing effect on the tar in a wide pH range, the phytic acid. is preferably  used with safety in a pH range of 4-8 in the mouth adjusted by a pH adjustor.  The acid extracted from a food, e.g. a grain, has the very high safety for the  human body.
Fibrosis is an abnormal tissue healing process characterized by the excessive accumulation of ECM components, such as COL I and COL III, in response to tissue injury or chronic inflammation. Recent advances in epitranscriptomics have underscored the importance of m6A modification in fibrosis. m6A, the most prevalent modification in eukaryotic RNA, is catalyzed by methyltransferases (e.g., METTL3), removed by demethylases (e.g., FTO), and recognized by reader proteins (e.g., YTHDF1/2). These modifications are crucial in regulating collagen metabolism and associated diseases. Understanding the role of m6A modification in fibrosis and other collagen-related conditions holds promise for developing targeted therapies. This review highlights the latest progress in this area.
Essentially pure HSV-2 UL26 gene products and fragments thereof including mature HSV-2 protease and active fragments thereof are disclosed. Essentially pure HSV-2 UL26.5 gene products and fragments thereof including mature HSV-2 capsid protein and functional fragments are disclosed. Isolated nucleic acid molecules comprising all or part of the HSV-2 UL26 gene and/or the HSV-2 UL26.5 gene are disclosed. Expression vectors and host cells comprising such nucleic acid molecules are disclosed. Methods of identifying compounds that inhibit HSV-2 protease activity and methods of identifying compounds that inhibit HSV-2 virion assembly are disclosed. Synthetic HSV-2 substrates are disclosed. Antibodies that selectively bind to HSV-2 protease processed substrates but not unprocessed substrates or unprocessed substrates but not processed substrates are disclosed. Methods of and kits for distinguishing between HSV-1 DNA or protein and HSV-2 DNA or protein and reagents useful in such methods and kits are disclosed.
The investigational medical product, the IN01 vaccine, will be administered in two phases to those patients in the experimental arm: the induction phase and the maintenance phase. During the induction phase IN01 vaccine will be administered on day 1 and will be repeated on Day 14, Day 28, Day 42 and day 56. During the maintenance phase, the vaccination will be administered every 2 months with the same dosage and administration mode as during induction.
PROBLEM TO BE SOLVED: To obtain a medicine for oral administration of teprenone, being a slurry excellent in a production stability (an emulsion stability), easily taken even by an elderly person of advanced age and suitable to an improvement of a gastric mucosa lesion, etc. SOLUTION: This medicine for oral administration of teprenone includes the teprenone as an active ingredient, fatty acid trigryceride and polyvinyl alcohol. The content of the teprenone is 0.1-10wt./vol. and the contents of the fatty acid trigryceride and the polyvinyl alcohol are respectively 0.05-4 pts.wt. and 0.1-5 pts.wt. based on 1 pt.wt. teprenone. The medicine has an emulsion state more stable than that of the medicine prepared by using neither the fatty acid triglyceride nor the polyvinyl alcohol and the lowering of the content of the teprenone is slight.
Patients receive tacrolimus and MMF as in arm II. Patients also receive sirolimus PO once daily on days -3 to 80.
Patients with MF receive ruxolitinib phosphate PO BID on days 1-28. Beginning course 4, patients also receive azacytidine SC or IV for 5 days. Treatment repeats every 28 days for 15 courses in the absence of disease progression or unacceptable toxicity.
BACKGROUND: Rapeseed (Brassica napus L.) is an important oil and industrial crop worldwide. Black rot caused by the bacterial pathogen Xanthomonas campestris pv. campestris (Xcc) is an infectious vascular disease that leads to considerable yield losses in rapeseed. Resistance improvement through genetic breeding is an effective and sustainable approach to control black rot disease in B. napus. However, the molecular mechanisms underlying Brassica-Xcc interactions are not yet fully understood, especially regarding the impact of post-transcriptional gene regulation via alternative splicing (AS).
RESULTS: In this study, we compared the AS landscapes of a susceptible parental line and two mutagenized B. napus lines with contrasting levels of black rot resistance. Different types of AS events were identified in these B. napus lines at three time points upon Xcc infection, among which intron retention was the most common AS type. A total of 1,932 genes was found to show differential AS patterns between different B. napus lines. Multiple defense-related differential alternative splicing (DAS) hub candidates were pinpointed through an isoform-based co-expression network analysis, including genes involved in pathogen recognition, defense signalling, transcriptional regulation, and oxidation reduction.
CONCLUSION: This study provides new insights into the potential effects of post-transcriptional regulation on immune responses in B. napus towards Xcc attack. These findings could be beneficial for the genetic improvement of B. napus to achieve durable black rot resistance in the future.
Patients receive TPST-1495 PO QD for 6 months in the absence of unacceptable toxicity. Patients also undergo EGD and GI endoscopy with biopsy at baseline and end of treatment and undergo blood sample collection throughout the study.
This is a post-hoc analysis using part of the patients involved in the Cross Iron Study (Anesthesiology. 2018 Oct;129(4):710-720 ) Included patients were all the patients scheduled for elective primary total hip or knee arthroplasty and assessed by an anesthesiologist involved in the Cross Iron Study. Exclusion criteria were pregnancy, age under 18 years old, systemic infection, bilateral arthroplasty, revision arthroplasty, and participation in a preoperative autologous donation program.

This was a observational study. The patient blood management program included: erythropoietin with iron supplementation if preoperative hemoglobin was lower than 13 g/dl; tranexamic acid during surgery; intravenous iron postoperatively and use of prespecified thresholds for homologous blood transfusion. Blood transfusion and anemia were assessed until day 5 or discharge, whichever came first. Major thromboembolic or cardiovascular events were assessed during admission and one month after discharge.
The invention provides an itraconazole/phospholipid composite including itraconazole and phospholipid according to the mass ratio of 1:0.5-15, wherein the itraconazole and the phospholipid are connected through intermolecular force. The composition significantly improves oil solubility of the itraconazole and solves the problems that the itraconazole is difficult to dissolve in both water and oil and is difficult to disperse in two phases of an emulsion. The invention secondly provides a preparation method for the itraconazole/phospholipid composite. The method is simple. The invention also provides an itraconazole sub-micro-emulsion which includes the itraconazole/phospholipid composite, oil for injection, a co-solvent, an emulsifying agent, an isoosmotic adjustment agent, a pH regulator and water for injection. On the basis of itraconazole, the drug loading amount of the itraconazole in the itraconazole sub-micro-emulsion is 0.5-9.0 mg/ml. The invention also provides a method, which is simple, for preparing the itraconazole sub-micro-emulsion. The itraconazole/phospholipid composite or the itraconazole sub-micro-emulsion is used for preparing a medicine treating superficial and systemic fungal infection.
Patients receive mitoxantrone hydrochloride IV over 30 minutes and ixabepilone IV over 3 hours on day 1 and oral prednisone twice daily on days 1-21. Treatment repeats every 21 days for ≥ 3 courses in the absence of disease progression or unacceptable toxicity.
INTRODUCTION: The relationship between cognitive function and subsequent sarcopenia remains unclear. Therefore, this study aimed to examine the associations of performance on multiple cognitive domains with sarcopenia in the middle-aged and older adults.
METHODS: This longitudinal analysis (wave 2011-2013) included 2,934 participants from the CHARLS study. Sarcopenia was defined by the Asian Sarcopenia Working Group 2019 criteria. Cognitive function was measured by the Chinese version of the Mini-Mental State Examination (MMSE). Three interpretable techniques, namely SHapley Additive exPlanations (SHAP) and two built-in methods (coefficients of logistic regression and Gini importance of random forest), were used to assess the relationship between MMSE, its components (orientation, attention, episodic memory, and visuospatial ability) and sarcopenia. In addition, the association of MMSE score and its components with sarcopenia was further validated using stepwise regression.
RESULTS: All interpretable methods showed that MMSE score was important predictors of sarcopenia, especially the SHAP (MMSE score ranked top one). For its components, episodic memory, visuospatial ability, and attention showed high predictive value compared with orientation. Stepwise regression analyses showed that MMSE score and its components of episodic memory and visuospatial ability were correlated with sarcopenia, with their odds ratios of 0.93 (95% CI: 0.91-0.96, p < 0.001), 0.87 (95% CI: 0.82-0.93, p < 0.001), and 1.32 (95% CI: 1.05-1.65, p = 0.016), respectively.
CONCLUSIONS: Better cognitive function especially episodic memory and visuospatial ability was negatively associated with incident sarcopenia among community middle-aged and older adults.
A system for processing data provided by medical devices. The system includes a medical device (10) having a memory device (230) configured to store medical device information. The system also includes an information system (350) connected to the medical device (10). The information system (350) includes at least a server (360) configured to receive at least a portion of the medical device information from the memory device (230) of the medical device (10). The server (360) is also configured to employ the medical device information to process at least one of patient data, prescription data and inventory/ordering data. The medical device information may include serial number data, device identifier data, operation data and/or usage data for the medical device (10). The patient data may include at least one of patient tracking data, patient recordkeeping data and patient billing data. The prescription data may include prescription issuance data, prescription filling data and prescription tracking data. The inventory/ordering data may include at least one of maintenance and replacement schedule data, administrator notification data, and automatically-generated medical device order data.
An isolated cell or cell line, wherein the cell is .beta.2-microglobulin deficient, neomycin-resistant and HAT-sensitive is provided. The cell FO-1 #12 is an example of a cell having these characteristics. A cell hybrid formed by the fusion of an FO-1 #12 cell or other cell described herein and a mammalian cell is provided. The patient-derived cell can be a tumor cell or other cell, such as a white blood cell. The patient-derived tumor cell can be a melanoma cell, a prostatic carcinoma cell, a colon carcinoma cell, a lung carcinoma cell, a breast carcinoma cell, a pancreatic carcinoma cell, or others. A method of treating AIDS in a patient, comprising administering to the patient a cell hybrid provided herein, wherein the patient-derived white blood cell is derived from the patient being treated, is provided. A method of treating solid tumor in a patient, comprising administering to the patient a cell hybrid as provided herein, wherein the patient-derived tumor cell is derived from the patient being treated, is provided.